Johnson & Johnson
General ticker "JNJ" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $360.3B
Johnson & Johnson does not follow the US Stock Market performance with the rate: -4.8%.
Estimated limits based on current volatility of 0.8%: low 143.37$, high 145.70$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends: last record date 2024-11-26, amount 1.24$ (Y3.41%)
- US accounted for 60.7% of revenue in the fiscal year ended 2023-01-01
- Price in estimated range
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [130.98$, 187.06$]
- 2024-12-30 to 2025-12-30 estimated range: [140.62$, 199.96$]
Financial Metrics affecting the JNJ estimates:
- Positive: Non-GAAP EPS, $ of 10.43 > 2.29
- Positive: Return on assets ratio (scaled to [-100,100]) of 17.34 > 7.10
- Positive: Operating profit margin, % of 27.49 > 19.51
- Negative: 0.14 < Interest expense per share, $ of 0.30
- Negative: Industry operating cash flow per share per price (median), % of -12.63 <= 3.85
- Positive: Inventory ratio change, % of 0.23 <= 1.08
Short-term JNJ quotes
Long-term JNJ plot with estimates
Financial data
| YTD | 2022-01-02 | 2023-01-01 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $78,740.00MM | $79,990.00MM | $85,159.00MM |
| Operating Expenses | $58,270.00MM | $56,797.00MM | $61,750.00MM |
| Operating Income | $20,470.00MM | $23,193.00MM | $23,409.00MM |
| Non-Operating Income | $-1,292.00MM | $-3,834.00MM | $-8,347.00MM |
| Interest Expense | $183.00MM | $276.00MM | $772.00MM |
| R&D Expense | $14,277.00MM | $14,135.00MM | $15,048.00MM |
| Income(Loss) | $19,178.00MM | $19,359.00MM | $15,062.00MM |
| Taxes | $1,377.00MM | $2,989.00MM | $1,736.00MM |
| Other Income(Loss) | $3,077.00MM | $1,571.00MM | $21,827.00MM |
| Profit(Loss) | $20,878.00MM | $17,941.00MM | $35,153.00MM |
| Stockholders Equity | $74,023.00MM | $76,804.00MM | $68,774.00MM |
| Inventory | $10,387.00MM | $10,268.00MM | $11,181.00MM |
| Assets | $182,018.00MM | $187,378.00MM | $167,558.00MM |
| Operating Cash Flow | $23,410.00MM | $21,194.00MM | $22,791.00MM |
| Capital expenditure | $3,652.00MM | $4,009.00MM | $4,543.00MM |
| Investing Cash Flow | $-8,683.00MM | $-12,371.00MM | $878.00MM |
| Financing Cash Flow | $-14,047.00MM | $-8,871.00MM | $-15,825.00MM |
| Earnings Per Share* | $7.93 | $6.86 | $13.88 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.